Anika Therapeutics, Inc. (AKP.F)
- Previous Close
24.00 - Open
23.40 - Bid 23.20 x 100000
- Ask 23.40 x 100000
- Day's Range
23.40 - 23.40 - 52 Week Range
15.80 - 26.40 - Volume
198 - Avg. Volume
3 - Market Cap (intraday)
346.987M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-4.82 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.67
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
www.anika.comRecent News: AKP.F
Performance Overview: AKP.F
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKP.F
Valuation Measures
Market Cap
347.25M
Enterprise Value
310.37M
Trailing P/E
--
Forward P/E
24.21
PEG Ratio (5yr expected)
2.42
Price/Sales (ttm)
2.26
Price/Book (mrq)
1.86
Enterprise Value/Revenue
2.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-45.39%
Return on Assets (ttm)
-1.81%
Return on Equity (ttm)
-31.61%
Revenue (ttm)
169.26M
Net Income Avi to Common (ttm)
-76.83M
Diluted EPS (ttm)
-4.82
Balance Sheet and Cash Flow
Total Cash (mrq)
68.63M
Total Debt/Equity (mrq)
13.65%
Levered Free Cash Flow (ttm)
6.54M
Research Analysis: AKP.F
Company Insights: AKP.F
AKP.F does not have Company Insights